EA201890153A1 - Ингибиторы поглощения глюкозы - Google Patents
Ингибиторы поглощения глюкозыInfo
- Publication number
- EA201890153A1 EA201890153A1 EA201890153A EA201890153A EA201890153A1 EA 201890153 A1 EA201890153 A1 EA 201890153A1 EA 201890153 A EA201890153 A EA 201890153A EA 201890153 A EA201890153 A EA 201890153A EA 201890153 A1 EA201890153 A1 EA 201890153A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- compounds
- absorption inhibitors
- glucose absorption
- uptake activity
- transporters
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
В данном документе предложены соединения, которые модулируют активность поглощения глюкозы и являются пригодными для лечения рака, аутоиммунных заболеваний, воспаления, инфекционных заболеваний и метаболических заболеваний. В некоторых вариантах реализации указанные соединения модулируют активность поглощения глюкозы посредством модулирования клеточных компонентов, включая, но не ограничиваясь ими, компоненты, связанные с гликолизом, и известные транспортеры/котранспортеры глюкозы, такие как GLUT1 и другие члены семейства GLUT/альтернативные транспортеры гексозы. В некоторых вариантах реализации изобретения соединения имеют структуру формулы Iгде переменные имеют значения, описанные в данном документе.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562185223P | 2015-06-26 | 2015-06-26 | |
PCT/US2016/039365 WO2016210330A1 (en) | 2015-06-26 | 2016-06-24 | Glucose uptake inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201890153A1 true EA201890153A1 (ru) | 2018-06-29 |
Family
ID=57586425
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201890153A EA201890153A1 (ru) | 2015-06-26 | 2016-06-24 | Ингибиторы поглощения глюкозы |
Country Status (8)
Country | Link |
---|---|
US (2) | US10273248B2 (ru) |
EP (1) | EP3313825A4 (ru) |
JP (1) | JP2018518518A (ru) |
CN (1) | CN108349910A (ru) |
CA (1) | CA3028355A1 (ru) |
EA (1) | EA201890153A1 (ru) |
HK (1) | HK1254835A1 (ru) |
WO (1) | WO2016210330A1 (ru) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7078960B2 (ja) * | 2017-01-26 | 2022-06-01 | エス. トサントリゾス,ヨウラ | 置換二環式ピリミジン系化合物および組成物ならびにその使用 |
US11071735B2 (en) | 2017-04-28 | 2021-07-27 | Kadmon Corporation, Llc | Treatment of inflammatory conditions and autoimmune diseases with glucose uptake inhibitors |
CN109020957B (zh) * | 2017-06-12 | 2023-01-13 | 南京天印健华医药科技有限公司 | 作为mnk抑制剂的杂环化合物 |
KR102469161B1 (ko) | 2017-06-30 | 2022-11-23 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | Rho-관련 단백질 키나아제 억제제, Rho-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 |
EP3421465B1 (en) | 2017-06-30 | 2022-10-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof |
CN110582489B (zh) | 2017-06-30 | 2023-10-27 | 北京泰德制药股份有限公司 | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 |
CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
WO2019126739A1 (en) | 2017-12-21 | 2019-06-27 | Shepherd Therapeutics, Inc. | Pyrvinium pamoate anti-cancer therapies |
WO2019173500A1 (en) | 2018-03-07 | 2019-09-12 | Duquesne University Of The Holy Spirit | PYRAZOLO[4,3-d]PYRIMIDINES AS ANTITUMOR AGENTS |
WO2020005935A1 (en) * | 2018-06-25 | 2020-01-02 | Kadmon Corporation, Llc | Glucose uptake inhibitors |
EP4058027A4 (en) * | 2019-11-13 | 2023-11-01 | Metabomed Ltd | GLUCOSE UPtake INHIBITORS AND THEIR USES |
AU2020395397A1 (en) * | 2019-12-02 | 2022-06-09 | Shanghai Yingli Pharmaceutical Co., Ltd | Oxygen-containing heterocyclic compound, preparation method and application thereof |
WO2022012409A1 (zh) * | 2020-07-14 | 2022-01-20 | 武汉朗来科技发展有限公司 | 一种rock抑制剂及其制备方法和用途 |
CN112479913A (zh) * | 2020-11-19 | 2021-03-12 | 安徽修一制药有限公司 | 一种n,n-二乙基氯代乙酰胺的制备方法 |
CN112741828B (zh) * | 2021-01-08 | 2022-04-26 | 武汉大学 | 药物联用物及其制备方法和用途 |
US20240109868A1 (en) * | 2022-08-29 | 2024-04-04 | Miracure Biotechnology Limited | Ep300/cbp modulator, preparation method therefor and use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003059913A1 (en) * | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
US8207178B2 (en) | 2007-12-14 | 2012-06-26 | Ardea Biosciences, Inc. | Fused pyrimidines as reverse transcriptase inhibitors |
CA2777762A1 (en) * | 2009-10-12 | 2011-04-21 | Myrexis, Inc. | Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon |
WO2012040499A2 (en) * | 2010-09-22 | 2012-03-29 | Surface Logix, Inc. | Metabolic inhibitors |
BR112013026521A2 (pt) * | 2011-04-21 | 2016-12-27 | Origenis Gmbh | pirazolo[4,3-d]pirimidinas úteis como inibidores de cinase |
CN102901456B (zh) | 2012-09-12 | 2015-10-28 | 深圳深蓝精机有限公司 | 检测装置及检测圆轴的外径、跳动值、真圆度的方法 |
EA201500362A1 (ru) * | 2012-10-05 | 2015-08-31 | Кадмон Корпорейшн, Ллк | Ингибиторы rho-киназы |
WO2016210331A1 (en) * | 2015-06-26 | 2016-12-29 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
-
2016
- 2016-06-24 EP EP16815426.8A patent/EP3313825A4/en not_active Withdrawn
- 2016-06-24 EA EA201890153A patent/EA201890153A1/ru unknown
- 2016-06-24 US US15/737,911 patent/US10273248B2/en active Active
- 2016-06-24 WO PCT/US2016/039365 patent/WO2016210330A1/en active Application Filing
- 2016-06-24 CN CN201680048825.8A patent/CN108349910A/zh active Pending
- 2016-06-24 CA CA3028355A patent/CA3028355A1/en not_active Abandoned
- 2016-06-24 JP JP2017567146A patent/JP2018518518A/ja not_active Ceased
-
2018
- 2018-10-31 HK HK18113929.9A patent/HK1254835A1/zh unknown
-
2019
- 2019-04-29 US US16/397,043 patent/US10988484B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HK1254835A1 (zh) | 2019-07-26 |
CA3028355A1 (en) | 2016-12-29 |
US20180298029A1 (en) | 2018-10-18 |
EP3313825A1 (en) | 2018-05-02 |
WO2016210330A1 (en) | 2016-12-29 |
US10273248B2 (en) | 2019-04-30 |
US20190315772A1 (en) | 2019-10-17 |
US10988484B2 (en) | 2021-04-27 |
CN108349910A (zh) | 2018-07-31 |
EP3313825A4 (en) | 2019-03-13 |
JP2018518518A (ja) | 2018-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201890153A1 (ru) | Ингибиторы поглощения глюкозы | |
EA201591327A1 (ru) | Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений | |
EA201891983A8 (ru) | Комбинированная терапия антителами к cd73 | |
EA201800367A1 (ru) | Способы лечения болезни хантингтона | |
PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
EA201690206A1 (ru) | Терапевтически активные соединения и способы их применения | |
EA201890754A1 (ru) | Соединения и способы их применения | |
EA201691845A1 (ru) | Фармацевтические композиции терапевтически активных соединений | |
EA201891732A1 (ru) | Биспецифичные связывающие белки для pd-l1 и kdr | |
EA201691492A1 (ru) | Диарильные макроциклы в качестве модуляторов протеинкиназ | |
EA201690617A1 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201500995A1 (ru) | Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения | |
EA201492002A1 (ru) | Противовирусные соединения | |
EA201401077A1 (ru) | Биспецифические антитела к человеческому tweak и человеческому il17 и их применения | |
EA201491816A1 (ru) | Дендримероподобные аминоамиды, обладающие активностью блокаторов натриевых каналов, для лечения сухости глаз и других заболеваний слизистых оболочек | |
EA201692525A1 (ru) | Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов | |
EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
EA201591618A1 (ru) | Замещенные имидазопиридазины | |
BR112017022281A2 (pt) | métodos para tratar câncer | |
MX2018009408A (es) | Rapaglutinas, nuevos inhibidores de transportadores de glucosa (glut) y uso de los mismos. | |
EA202091360A1 (ru) | Гуманизированные анти-liv1 антитела для лечения рака молочной железы | |
EA201791814A1 (ru) | Имидазолильные трициклические еноны как антиоксидантные модуляторы воспаления | |
EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA201690880A1 (ru) | Тетрациклические ингибиторы аутотаксина | |
MX2022007671A (es) | Compuestos antihelminticos que comprenden una estructura de azaindoles. |